-
Family planning clinicians are familiar with the injectable contraceptive depot medroxyprogesterone acetate (DMPA) as an effective form of reversible birth control, following only the contraceptive implant and intrauterine device (IUD) in contraceptive efficacy.
-
Results from a multi-country clinical trial of a combined oral contraceptive (OC) containing nomegestrol acetate and 17-beta estradiol indicate it is an effective pill with good cycle control.
-
As of this writing, in mid-May, policymaking at the federal level was at a standstill, with lawmakers waiting on two major events: the Supreme Court's June decision on the Affordable Care Act and the November national elections. So, for this month's column, we'll turn our attention to the state level, where policymakers are having another busy year.
-
Look for new labeling on combined oral contraceptives (OCs) containing drospirenone following the Food and Drug Administration's (FDA) review of studies regarding the risk of blood clots in women using such formulations.
-
Pre-exposure prophylaxis (PrEP) for HIV prevention has taken a giant step forward with a Food and Drug Administration (FDA) committee's recommendation for approval of a specific drug for such use.
-
-
-
In 1992, reproductive health advocates estimated that widespread use of emergency contraceptive pills (ECPs) could prevent half of all U.S. unintended pregnancies and abortions.
-
About three million U.S. women experience heavy menstrual bleeding each year.1 With the recent Food and Drug Administration (FDA) approval of Natazia (Bayer HealthCare Pharmaceuticals, Wayne, NJ) for treatment in women who choose an oral contraceptive (OC), clinicians now have another therapeutic option.
-
How many chlamydia tests were performed on sexually active women ages 15-25 in your clinic last year? If your numbers are similar to a new national analysis, about 38% of sexually active young women ages 15-25 were screened for the sexually transmitted disease (STD).
